Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM: Safety of Recycled Cartilage and Allogeneic MSCs for Knee Cartilage Defects
NCT03672825Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2018
- Primary completion
- May 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous chondrons + allogeneic mesenchymal stromal cells in cartilage defect, sponsored by Mayo Clinic. Primary endpoint: Nature, incidence and severity of adverse events at 2 years. Started Sep 2018; status: completed.
02
Drugs
autologous chondrons + allogeneic mesenchymal stromal cells
03
Conditions
cartilage defect
Beyond the preview
Go deeper on NCT03672825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672825.